pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Lyfgenia
drug · gene
save

lovotibeglogene autotemcel

Phase 3updated 6mo ago
by Genetix Biotherapeutics Inc🔗 ChEMBL
Phase 3
community read0 votes

Gene drug with a maximum clinical stage of Approval, with an approval for sickle cell disease.

indications

indications
Sickle Cell Disease

targets

Hemoglobin subunit beta

all catalysts(0)

nothing on the calendar yet

News(7)

  • Genetix’s genetic medicines are officially profitable, with $327M in sales YTD
    It’s been a long road to financial stability for Genetix Biotherapeutics, the rebranded name of bluebird bio following its February 2025 sale to two private equity firms, but on Monday the biotech…
    biospace · 2d ago
  • Marrow Therapeutics debuts with $173M to tackle blood disorders in vivo
    Marrow Therapeutics aims to address safety and accessibility obstacles in genetic medicines by delivering therapies straight to bone marrow cells.
    biospace · 2d ago
  • Marrow sets out to challenge genetic medicines for severe blood diseases
    Armed with $173 million in venture funding, the startup is developing what it’s positioning as a more accessible alternative to gene therapy and gene editing treatments for sickle cell and beta tha…
    biopharma_dive · 2d ago
  • Marrow extracts $120M series B to advance preclinical blood disease therapy
    A new biotech targeting blood disorders, aptly called Marrow Therapeutics, has launched with $173 million in combined funding and a preclinical lead program aimed at sickle cell disease and beta th…
    fiercebiotech · 6d ago
  • Beam’s base editing therapy for sickle cell hits goal in pivotal trial
    The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.
    biopharma_dive · 8d ago
  • Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdown
    Gearing up for a potential FDA filing by the end of the year, Beam Therapeutics revealed results from a phase 1/2 study of its base-edited cell therapy risto-cel, showing the potential sickle cell…
    fiercebiotech · 8d ago
  • New FDA draft guidance doubles down on expediting approvals of personalized gene therapies
    The FDA has outlined a process for allowing a single application to cover multiple variants of a gene therapy. At the same time, the Centers for Medicare & Medicaid Services has revealed plans to e…
    biospace · 21d ago
brand
Lyfgenia
trade names
Lyfgenia
generic
lovotibeglogene autotemcel
MOA
Hemoglobin beta chain exogenous gene
indication
Sickle Cell Disease
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?